Skip to main content

Carcinoma, Intraductal, Noninfiltrating clinical trials at UCSF

1 research study open to eligible people

Carcinoma, Intraductal, Noninfiltrating is a type of breast cancer that stays inside the ducts. UCSF is now recruiting for a clinical trial called "Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)." The trial studies the change in the immune system of high risk DCIS after taking pembrolizumab for a short time.

Showing trials for
  • Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

    open to eligible females ages 18 years and up

    This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.

    San Francisco, California

Our lead scientists for Carcinoma, Intraductal, Noninfiltrating research studies include .

Last updated: